Recombinant Human TP53 protein
Cat.No. : | TP53-185H |
Product Overview : | Recombinant Full-length human wild type p53 (393aa, derived from BC003596) was expressed in E. coli. |
- Specification
- Gene Information
- Related Products
- Download
Source : | E. coli |
Species : | Human |
Form : | 0.50 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT. |
AA Sequence : | MEEPQSDPSVEPPLSQETFSDLWKL LPENNVLSPLPSQAMDDLMLSPDDI EQWFTEDPGPDEAPRMPEAAPRVAP APAAPTPAAPAPAPSWPLSSSVPSQ KTYQGSYGFRLGFLHSGTAKSVTCT YSPALNKMFCQLAKTCPVQLWVDST PPPGTRVRAMAIYKQSQHMTEVVRR CPHHERCSDSDGLAPPQHLIRVEGN LRVEYLDDRNTFRHSVVVPYEPPEV GSDCTTIHYNYMCNSSCMGGMNRRP ILTIITLEDSSGNLLGRNSFEVRVC ACAGRDRRTEEENLRKKGEPHHELP PGSTKRALPNNTSSSPQPKKKPLDG EYFTLQIRGRERFEMFRELNEALEL KDAQAGKEPGGSRAHSSHLKSKKGQ STSRHKKLMFKTEGPDSD |
Purity : | >90% by SDS-PAGE |
Storage : | Keep at -80 centigrade for long term storage. Product is stable at 4 centigrade for at least 7 days. |
Tag : | Non |
Publication : |
Imaging and kinetics of the bimolecular complex formed by the tumor suppressor p53 with ubiquitin ligase COP1 as studied by atomic force microscopy and surface plasmon resonance (2018)
Surface enhanced Raman spectroscopy based immunosensor for ultrasensitive and selective detection of wild type p53 and mutant p53R175H (2018)
|
Gene Name : | TP53 tumor protein p53 [ Homo sapiens ] |
Official Symbol : | TP53 |
Synonyms : | TP53; tumor protein p53; cellular tumor antigen p53; LFS1; Li Fraumeni syndrome; p53; antigen NY-CO-13; mutant p53 protein; phosphoprotein p53; p53 tumor suppressor; truncated p53 protein; tumor suppressor TP53; transformation-related protein 53; P53; TRP53; FLJ92943; |
Gene ID : | 7157 |
mRNA Refseq : | NM_000546 |
Protein Refseq : | NP_000537 |
MIM : | 191170 |
UniProt ID : | P04637 |
Chromosome Location : | 17p13.1 |
Pathway : | Activation of BH3-only proteins, organism-specific biosystem; Activation of NOXA and translocation to mitochondria, organism-specific biosystem; Activation of PUMA and translocation to mitochondria, organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), organism-specific biosystem; Amyotrophic lateral sclerosis (ALS), conserved biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Apoptosis, organism-specific biosystem; |
Function : | ATP binding; DNA binding; DNA strand annealing activity; MDM2 binding; RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; RNA polymerase II transcri |
Products Types
◆ Recombinant Protein | ||
TP53-5676H | Recombinant Human TP53 protein, His-tagged | +Inquiry |
TP53-2548H | Recombinant Human TP53 protein(101-310 aa), N-MBP & C-His-tagged | +Inquiry |
TP53-4922H | Recombinant Human TP53 protein(1-393aa(R273H)), His-tagged | +Inquiry |
TP53-30574H | Recombinant Human TP53 Protein, GST-tagged | +Inquiry |
TP53-983H | Recombinant Human TP53 Protein, His-tagged | +Inquiry |
◆ Lysates | ||
TP53-860HCL | Recombinant Human TP53 293 Cell Lysate | +Inquiry |
Related Gene
Not For Human Consumption!
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewBy actively engaging with researchers and understanding their needs, manufacturers can contribute significantly to the success and impact of research involving the TP53 protein.
This flexibility allows for tailored approaches and provides researchers with more options to study specific aspects of TP53 biology or its interactions with other molecules.
Manufacturers can provide comprehensive product information, including data on the functionality, stability, and handling of TP53 protein.
Q&As (5)
Ask a questionYes, identifying TP53 mutations in families with a history of early-onset cancers can help identify individuals at high risk for cancer and guide screening and prevention strategies.
TP53 mutations are highly diverse, making it challenging to develop a one-size-fits-all therapy. Additionally, the p53 pathway is complex, and disrupting it can have unintended consequences.
Yes, TP53 mutation status can be a criterion for eligibility in specific clinical trials, especially those testing experimental treatments that may target the p53 pathway.
TP53 status can influence treatment decisions. For example, patients with TP53 mutations may require more aggressive treatment approaches or different chemotherapy regimens.
Currently, there are no specific targeted therapies approved solely for TP53-mutated cancers. However, research is ongoing to develop drugs that target the altered p53 pathway.
Ask a Question for All TP53 Products
Required fields are marked with *
My Review for All TP53 Products
Required fields are marked with *
Inquiry Basket